Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309452 · ClinicalTrials.gov registry record · NA
Specialized Treatment Early in Psychosis (STEP)
A NA study of Schizophrenia and Disorders With Psychotic Features, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00309452 is a NA study of Schizophrenia and Disorders With Psychotic Features that has completed, run by Yale University. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00309452, a NA study of Schizophrenia and Disorders With Psychotic Features, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive remediation
- BEHAVIORAL MFG
- BEHAVIORAL Cognitive Behavioral Group Therapy
- DRUG Medications
- BEHAVIORAL Assertive case management
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309452
The ClinicalTrials.gov registry entry for NCT00309452 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia and Disorders With Psychotic Features appearing as the primary indexed condition, and to 5 interventions - of which Cognitive remediation is the first listed.
NCT00309452 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00309452 about?
NCT00309452 is a clinical study titled "Specialized Treatment Early in Psychosis (STEP)". The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.
What is the current status of trial NCT00309452?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2006-03. Estimated completion is 2013-08.
What conditions does trial NCT00309452 study?
This clinical trial studies the following conditions: Schizophrenia and Disorders With Psychotic Features.
What interventions are being tested in trial NCT00309452?
The interventions under investigation include: Cognitive remediation (BEHAVIORAL), MFG (BEHAVIORAL), Cognitive Behavioral Group Therapy (BEHAVIORAL), Medications (DRUG), Assertive case management (BEHAVIORAL).
Who is sponsoring clinical trial NCT00309452?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00309452 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.